923 related articles for article (PubMed ID: 24184687)
1. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
Myint AM; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
[TBL] [Abstract][Full Text] [Related]
2. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
3. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression.
Maes M; Leonard BE; Myint AM; Kubera M; Verkerk R
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Apr; 35(3):702-21. PubMed ID: 21185346
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
5. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
6. Kynurenine pathway in Parkinson's disease-An update.
Venkatesan D; Iyer M; Narayanasamy A; Siva K; Vellingiri B
eNeurologicalSci; 2020 Dec; 21():100270. PubMed ID: 33134567
[TBL] [Abstract][Full Text] [Related]
7. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
8. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
Wichers MC; Koek GH; Robaeys G; Verkerk R; Scharpé S; Maes M
Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
[TBL] [Abstract][Full Text] [Related]
9. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation.
Hughes MM; Carballedo A; McLoughlin DM; Amico F; Harkin A; Frodl T; Connor TJ
Brain Behav Immun; 2012 Aug; 26(6):979-87. PubMed ID: 22683764
[TBL] [Abstract][Full Text] [Related]
10. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression.
Wichers MC; Maes M
J Psychiatry Neurosci; 2004 Jan; 29(1):11-7. PubMed ID: 14719046
[TBL] [Abstract][Full Text] [Related]
11. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression.
Miura H; Ozaki N; Sawada M; Isobe K; Ohta T; Nagatsu T
Stress; 2008 May; 11(3):198-209. PubMed ID: 18465467
[TBL] [Abstract][Full Text] [Related]
12. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
[TBL] [Abstract][Full Text] [Related]
13. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the immune-inflammatory and the kynurenine pathways in rats resistant to antidepressant treatment in model of depression.
Duda W; Curzytek K; Kubera M; Connor TJ; Fagan EM; Basta-Kaim A; Trojan E; Papp M; Gruca P; Budziszewska B; Leśkiewicz M; Maes M; Lasoń W
Int Immunopharmacol; 2019 Aug; 73():527-538. PubMed ID: 31176083
[TBL] [Abstract][Full Text] [Related]
15. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
16. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.
Müller N; Schwarz MJ
Mol Psychiatry; 2007 Nov; 12(11):988-1000. PubMed ID: 17457312
[TBL] [Abstract][Full Text] [Related]
17. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
18. The kynurenine pathway in brain tumor pathogenesis.
Adams S; Braidy N; Bessede A; Brew BJ; Grant R; Teo C; Guillemin GJ
Cancer Res; 2012 Nov; 72(22):5649-57. PubMed ID: 23144293
[TBL] [Abstract][Full Text] [Related]
19. [Depression and inflammation in rheumatic diseases].
Buras A; Waszkiewicz N; Szulc A
Postepy Hig Med Dosw (Online); 2016 Mar; 70():162-8. PubMed ID: 26943313
[TBL] [Abstract][Full Text] [Related]
20. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
